Hansa Biopharma: Supportive top-line clinical results in sequential gene therapy combination
4 augusti, 10:19
4 augusti, 10:19
The combination of ELEVIDYS from Sarepta and Imlifidase records early supportive top-line data for patients resistant to ELEVIDYS when treating three Duchenne muscular dystrophy (DMD) patients.
4 augusti, 10:19
The combination of ELEVIDYS from Sarepta and Imlifidase records early supportive top-line data for patients resistant to ELEVIDYS when treating three Duchenne muscular dystrophy (DMD) patients.
Aktieråd
Analys
Bostadsmarknaden
Aktieråd
Analys
Bostadsmarknaden
1 DAG %
Senast
OMX Stockholm 30
1 DAG %
Senast
2 562,75